fludarabine + rituximab + pixantrone

A combination regimen of fludarabine, rituximab, and pixantrone (often referred to as FPD-R) is used primarily in the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (NHL). Fludarabine is a purine analog that inhibits DNA synthesis by interfering with DNA polymerase and ribonucleotide reductase. Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes, leading to cell lysis via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Pixantrone is an aza-anthracenedione designed to reduce cardiotoxicity compared to traditional anthracyclines; it induces cell death through DNA alkylation, formation of double-strand breaks, and disruption of mitosis. The FPD-R regimen has demonstrated high response rates and durable remissions in clinical trials for patients with relapsed or refractory indolent NHL[1][3][8].

Other names

FPD-R